Autonomix Medical, Inc. AMIX
1.08 USD -0.02 (-1.82%)
Regular-session close
1.10 +0.02 +1.85%
After hours · Nov 17, 7:35 PM ET
1.06 Day range 1.22
0.932 52-week range 24.68
- YTD
- -90.65%
- 1 year
- -95.53%
News
globenewswire.com Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026 Microchip-enabled sensing platform aims to combine signal acquisition, mapping and real-time catheter positioning to support future nerve-targeted procedures
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Lisata Therapeutics (NASDAQ:LSTA) stock rose 37.2% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. BioStem Technologies…
globenewswire.com Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology Latest patent expands intellectual property protection for advanced physiological signal acquisition and processingbenzinga.com Autonomix Medical Will Be Issued U.S. Patent Number 12,793,841 Tomorrow Titled "MEDICAL DEVICES WITH CIRCUITRY FOR CAPTURING AND PROCESSING PHYSIOLOGICAL SIGNALS" https://patentcenter.uspto.gov/applications/19004748/ifw/docshttps://x.com/PatentGrants/status/2119896998711362028
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
globenewswire.com Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
globenewswire.com Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its…
globenewswire.com Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio
globenewswire.com Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies
globenewswire.com Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026 Abstracts highlight potential of Autonomix's transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc.…
globenewswire.com Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer…
globenewswire.com Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted…
globenewswire.com Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix”…
globenewswire.com Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care
benzinga.com Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent Autonomix Medical Inc. (NASDAQ:AMIX) shares are skyrocketing Tuesday afternoon after securing U.S. Patent No. 12,433,670.
globenewswire.com Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain
globenewswire.com Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation THE WOODLANDS, TX, July 24, 2026…
globenewswire.com Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications…
globenewswire.com Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted…
proactiveinvestors.com Autonomix Medical wins new patent for neural sensing technology Autonomix Medical Inc (NASDAQ:AMIX) has been granted a new patent strengthening its neural sensing intellectual property, the company said, adding to a portfolio it ties to what it called the…
